Literature DB >> 9228252

The basement membrane and tumor progression in the uterine cervix.

S A Nair1, M B Nair, P G Jayaprakash, T N Rajalekshmy, M K Nair, M R Pillai.   

Abstract

Immunocytochemical localization of the basement membrane (BM) proteins laminin, type-IV collagen and fibronectin were analyzed in normal cervical epithelium, low grade squamous intraepithelial lesions (SILs), high grade SILs and invasive squamous cell carcinoma (SCC) of the uterine cervix. A regular, thick and continuous BM was present in normal cervical epithelium and low grade SIL. Interruptions and discontinuity of the BM were more evident in high grade SILs. There was a good correlation between increasing severity of the lesion and increasing number of breaks. In SCC, the distribution of laminin, collagen IV and fibronectin was related to the degree of cellular differentiation, with decreased immunoreactivity being evident in moderately and poorly differentiated tumors. As the invasive potential of the tumor increased, the fragmentation and loss of BM was more evident. Fibronectin showed only moderate to mild immunoreactivity in normal cervical epithelium and low grade SILs. However, the intensity of expression increased in high grade SILs especially in the peritumoral stroma. It may therefore be concluded from these results that snythesis and reabsorption of BM proteins may be related to shifts in cellular metabolism during tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9228252

Source DB:  PubMed          Journal:  Gen Diagn Pathol        ISSN: 0947-823X


  2 in total

1.  Changes in matrix metalloproteinases and their endogenous inhibitors during tumor progression in the uterine cervix.

Authors:  S Asha Nair; D Karunagaran; M B Nair; P R Sudhakaran
Journal:  J Cancer Res Clin Oncol       Date:  2003-02-19       Impact factor: 4.553

2.  β1 integrin: an emerging player in the modulation of tumorigenesis and response to therapy.

Authors:  Grant A Howe; Christina L Addison
Journal:  Cell Adh Migr       Date:  2012-03-01       Impact factor: 3.405

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.